As part of WHO’s global strategy for the containment of resistance to antimicrobial drugs, and in collaboration with Member States, WHO is invited to:
1. Bring together national authorities for human and veterinary drug regulation to exchange information and to consider joint action.
2. Provide guidance on the clinical development of antimicrobial drugs, in particular to optimize efficacy while minimizing the risk of resistance.
3. Establish a common format for product information and patient information leaflets, specifically addressing antimicrobial resistance issues such as specifications for medicines, susceptibility of common pathogens and measures to prevent resistance. Special attention should be given to improving the communicative potential of the information provided. This information should be regularly updated in the light of prevailing resistance patterns.
4. Continue efforts, as set out in WHO resolution WHA 51.17, to make antimicrobial drugs available on a prescription-only basis.
5. Stimulate drug regulatory authorities to share all relevant information on clinical trials involving antimicrobial drugs, with public health authorities.